Free Trial
→ Did you grab your copy yet? (From Profits Run) (Ad)tc pixel
NYSE:ANVS

Annovis Bio Q3 2026 Earnings Date & Estimates

Annovis Bio logo
$1.02 -0.04 (-3.30%)
Closing price 03:59 PM Eastern
Extended Trading
$1.02 0.00 (0.00%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Annovis Bio is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026. The conference call is scheduled for November 10, 2026 at 12:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Conference Call Date
Conference Call
12:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Annovis Bio in Q3 2026

Annovis Bio is expected to post earnings of -$0.30 per share. In the same quarter a year earlier Annovis Bio reported -$0.37 per share. Annovis Bio last reported on August 14, 2026, posting -$0.40 per share and beating the -$0.4533 consensus estimate. Annovis Bio has beaten the consensus EPS estimate in 3 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.30
Prior-Year EPS
-$0.37

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.40 (Beat by +$0.0533)
EPS Beat Rate
3 of last 8 quarters

Prepare for the Q3 2026 Call

Annovis Bio Q3 2026 Earnings FAQ

Annovis Bio (NYSE:ANVS) is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Annovis Bio's Q3 2026 earnings conference call is scheduled for Tuesday, November 10, 2026 at 12:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Annovis Bio to post earnings of -$0.30 per share for Q3 2026.

Annovis Bio Earnings Headlines

Annovis Collaborates With Weave Bio On AI Use In NDA Submission For Butanetap
September 23, 2026  |  rttnews.comhttps://www.rttnews.com/3693317/annovis-collaborates-with-weave-bio-on-ai-use-in-nda-submission-for-butanetap.aspx
Annovis Announces Partnership with Weave Bio, AI Regulatory Platform, in Preparation of NDA for Buntanetap in Alzheimer’s Disease
September 23, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/annovis-announces-partnership-with-weave-bio-ai-regulatory-platform-in-preparation-of-nda-for-buntanetap-in-alzheimer-s-disease-1036567137
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid. The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned.tc pixel
October 14 at 1:00 AM  |  Awesomely (Ad)
Annovis Announces Partnership with Weave Bio, AI Regulatory Platform, in Preparation of NDA for Buntanetap in Alzheimer's Disease
September 23, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/23/3367426/0/en/annovis-announces-partnership-with-weave-bio-ai-regulatory-platform-in-preparation-of-nda-for-buntanetap-in-alzheimer-s-disease.html
Annovis Bio consensus price target lowered by 16.67% to $10.71
September 15, 2026  |  msn.comhttps://www.msn.com/en-us/money/other/annovis-bio-consensus-price-target-lowered-by-16-67-to-10-71/ar-AA2ceUho
Analysts Are Bullish on Top Healthcare Stocks: Annovis Bio (ANVS), AbbVie (ABBV)
September 5, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/ABBV/pressreleases/4461256/analysts-are-bullish-on-top-healthcare-stocks-annovis-bio-anvs-abbvie-abbv/
See More Annovis Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Annovis Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Annovis Bio and other key companies, straight to your email.

About Annovis Bio

Annovis Bio (NYSE:ANVS) is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease. The company’s research centers on treatments designed to address the underlying mechanisms that contribute to the accumulation of multiple neurotoxic proteins in the brain.

Annovis’ lead drug candidate is buntanetap, formerly known as ANVS401. The orally administered small-molecule therapy is being developed to reduce the production of several neurotoxic proteins, including amyloid beta, tau and alpha-synuclein, which are associated with neurodegenerative disorders. The company has evaluated buntanetap in clinical studies involving patients with Alzheimer’s and Parkinson’s disease.

Annovis Bio was founded in 2008 and is headquartered in Berwyn, Pennsylvania. The company’s operations are focused on research and clinical development, with its programs subject to ongoing evaluation for safety and effectiveness. Maria Maccecchini, Ph.D., the company’s founder, serves as president and chief executive officer.

View Annovis Bio Profile
Earnings Tools